---
title: 'Reimbursement in the Context of Precision Oncology Approaches in Metastatic
  Breast Cancer: Challenges and Experiences'
date: '2024-02-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38384493/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240222170805&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Precision oncology programs using next-generation sequencing
  to detect predictive biomarkers are extending therapeutic options for patients with
  metastatic breast cancer (mBC). Regularly, based on the recommendations of the interdisciplinary
  molecular tumor board (iMTB), an inclusion in a clinical trial is not possible.
  In this case, the German health insurance system allows for the application of reimbursement
  for an off-label drug use. Here, we describe the current challenges ...'
disable_comments: true
---
BACKGROUND: Precision oncology programs using next-generation sequencing to detect predictive biomarkers are extending therapeutic options for patients with metastatic breast cancer (mBC). Regularly, based on the recommendations of the interdisciplinary molecular tumor board (iMTB), an inclusion in a clinical trial is not possible. In this case, the German health insurance system allows for the application of reimbursement for an off-label drug use. Here, we describe the current challenges ...